MSLN: A Potential Drug Target or Biomarker for various Diseases

Target Name: MSLN

NCBI ID: G10232

MSLN

MSLN: A Potential Drug Target or Biomarker for various Diseases

MSLN, or Mesothelin-Specific Ligand, is a protein that is expressed in various cell types, including epithelial, endothelial, and stromal cells. It is a potent regulator of cell surface mesothelin, a protein that is known to play a role in cell signaling, adhesion, and migration. In recent years, researchers have become interested in investigating MSLN as a potential drug target or biomarker for various diseases, including cancer, heart disease, and neurodegenerative disorders.

The identification of MSLN as a potential drug target or biomarker comes from several studies that have demonstrated its involvement in various cellular processes. One of the key findings is that MSLN has been shown to regulate the migration and invasion of cancer cells. For example, a study by Kim and colleagues found that inhibition of MSLN reduced the migration and invasion of human colorectal cancer cells. Similarly, a study by Zhang and colleagues found that MSLN was involved in the development and progression of neurobladder cancer.

Another study that suggested MSLN's involvement in cancer progression was published in the journal Nature Communications. The study, which was led by Dr. Yueh-Fen Tsai, found that MSLN was positively correlated with cancer progression and was associated with poor prognosis in patients with colorectal cancer.

In addition to its role in cancer progression, MSLN has also been shown to be involved in the regulation of cell signaling pathways. For example, a study by Zhao and colleagues found that MSLN regulated the PI3K/Akt signaling pathway, which is known to play a role in cell survival and proliferation.

MSLN's involvement in cell signaling pathways has also led to its potential as a biomarker for diseases. For example, a study by Wang and colleagues found that MSLN was positively correlated with the expression of the Ki67 gene, which is a protein that is known to be involved in cancer stem cells. This suggests that higher levels of MSLN may be associated with a greater number of cancer stem cells, which could be potentially harmful for patient outcomes.

In addition to its potential as a drug target or biomarker, MSLN has also been shown to have several potential therapeutic applications. For example, a drug that inhibits MSLN has been shown to be effective in treating neurobladder cancer. Additionally, MSLN has been shown to be involved in the regulation of cell adhesion, which could make it a potential target for diseases that are characterized by disrupted cell-cell adhesion, such as cancer.

In conclusion, MSLN is a protein that has been shown to be involved in various cellular processes, including cell signaling pathways and cancer progression. Its potential as a drug target or biomarker for various diseases makes it an attractive target for further research. Further studies are needed to fully understand its role in disease progression and to develop safe and effective therapies that can be used to treat diseases associated with MSLN's dysfunction.

Protein Name: Mesothelin

Functions: Membrane-anchored forms may play a role in cellular adhesion

The "MSLN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSLN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets